Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Why Boy Scout Releases Were OK Despite Failing Purdue Test No Photo Available

Rick Archer

The Third Circuit's rejection of challenges to third-party releases in the Boy Scouts of America's Chapter 11 plan may appear at odds ... (more story)

Restaurant Headwinds Blew Bertucci's To 3rd Ch. 11 No Photo Available

Clara Geoghegan

Italian dining chain Bertucci's filed for bankruptcy in Florida last month, marking its third Chapter 11 case in seven years as many r... (more story)

Lack Of Fundamental Change Led To Rite Aid's Ch. 22 Case No Photo Available

Vince Sullivan

Pharmacy chain Rite Aid commenced its second Chapter 11 case since 2023 last week, falling back into bankruptcy so soon because its fa... (more story)